552287-61-3

Upstream product

• 544710-37-4 4-{1-Carbethoxy-2-[3,4-bis(difluoromethoxy)phenyl]-2-(6-bromo-pyridin-3-yl)ethyl}pyridine 
• 303165-20-0 (+/-)-[3,4-bis(difluoromethoxy)phenyl]-(2-bromopyridin-5-yl)methanol 
• 544710-36-3 [3,4-Bis(difluoromethoxy)phenyl]-(6-bromo-pyridin-3-yl)chloromethane 
• 127842-54-0 3,4-bis-(difluoromethoxy)-benzaldehyde 
• 624-28-2 2,5-dibromopyridine 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 303165-22-2 (+/-)-4-{2-[3,4-bis(difluoromethoxy)phenyl]-2-[5-(2-bromo)pyridyl]ethyl}pyridine 

Downstream Products

• 592533-99-8 5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-pyridin-4-yl-ethyl]-pyridine-2-carboxylic acid methoxy-methyl-amide 
• 552287-62-4 (+/-)-4-{2-[3,4-bis(difluoromethoxy)phenyl]-2-[5-(2-carbomethoxy)pyridyl]ethyl}pyridine N-oxide 
• 592533-97-6 1-{5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-pyridin-4-yl-ethyl]-pyridin-2-yl}-ethanone 
• 592533-98-7 1-{5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-(1-oxy-pyridin-4-yl)-ethyl]-pyridin-2-yl}-ethanone 
• 290307-05-0 {5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-pyridin-4-yl-ethyl]-pyridin-2-yl}-phenyl-methanone 
• 290307-25-4 {5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-pyridin-4-yl-ethyl]-pyridin-2-yl}-thiazol-2-yl-methanone 
• 290307-01-6 1-{5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-pyridin-4-yl-ethyl]-pyridin-2-yl}-pentan-1-one 
• 290307-07-2 {5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-(1-oxy-pyridin-4-yl)-ethyl]-pyridin-2-yl}-phenyl-methanone 
• 290307-26-5 {5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-(1-oxy-pyridin-4-yl)-ethyl]-pyridin-2-yl}-thiazol-2-yl-methanone 
• 290307-02-7 1-{5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-(1-oxy-pyridin-4-yl)-ethyl]-pyridin-2-yl}-pentan-1-one 
• 290307-03-8 {5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-pyridin-4-yl-ethyl]-pyridin-2-yl}-cyclohexyl-methanone 
• 290307-04-9 {5-[1-(3,4-bis-difluoromethoxy-phenyl)-2-(1-oxy-pyridin-4-yl)-ethyl]-pyridin-2-yl}-cyclohexyl-methanone 

Relevant academic research and scientific papers

Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: Structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity

A SAR study on the tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors related to 1 is described. In addition to inhibitory potency against PDE4 and the lipopolysaccharide-induced production of TNFα in human whole blood, the binding affinity

Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors

The synthesis and the phosphodiesterase-4 (PDE4) inhibitory activity of 2-pyridinemethanol derivatives is described. The evaluation of the structure-activity relationship (SAR) in this series of novel PDE4 inhibitors led to the identification of compound